Lykera Biomed

Lykera is a biotech based in Barcelona. It'ss developing biologics for the treatment of cancer by targeting tumour cells, stromal cells and angiogenesis

[Pancreas Online @PANCREASonline]

Ahead of Print: Primary Mesenchymal Tumors of the Pancreas: Single-Center Experience Over 16 Years: Objective:... http://t.co/JyHo174RnF

[ASCO @ASCO]

What's the State of Cancer Care in America? In 10 mins, join our live stream http://t.co/8tu7T7OTBU #CancerCareAmerica

[Lykera Biomed @Lykera]

Therapeutic Targeting of Tumor Growth and #Angiogenesis with a Novel Anti-S100A4 Monoclonal Antibody #PlosOne #cancer http://t.co/E7kpIpmEPk

[PharmaTimes @PharmaTimes]

PT News: B-MS signs up Samsung to make Yervoy http://t.co/cEDhalpsdO #pharmaceuticals

[JCI Nederland @JCINederland]

#JCINL Daily is out! http://t.co/sB1beTNKlD ▸ Top stories today via @jciprograms @Lykera

[Advancell @Advancell_sa]

Helsinn and Advancell sign a partnering agreement for ATH008, a new compound for chemotherapy-induced dermatological injuries

[Lykera Biomed @Lykera]

Nanoparticle clearance governed by Th1/Th2 immunity and strain background http://t.co/EY6gUZXD3C #nanotechnology #research #jci #nanomed

[Lykera Biomed @Lykera]

Original paper on anti-#CD47 #antibody #cancer #research http://t.co/I27I0S6tAg #pnas

[EuropaBio @EuropaBio]

New Annual Report is now available.See the work our sectors having been doing to raise the profile of EU biotech:http://t.co/OsLkqHC5bV

[Col·legi Metges BCN @COMBarcelona]

Lykera Biomed, tractament càncer per cèl•lules de l’estroma del tumor i angiogènesi http://t.co/tf2n0CEV29 #forumhealthcare #biotecnologia

[Biocat @biocat_en]

Ten companies seek capital at 10th #Healthcare #Barcelona Investment Forum @MIHealthForum: http://t.co/IW4qkdYs0V

[MMS @mmsholdings]

FDA Accelerated Approval of Oncology Drugs http://t.co/ULWXtkruk2 Overnight success and regulatory pathways.

[Biocat @biocat_en]

Pancreatic #cancer treatment from @Lykera, ready for regulatory preclinical phase: http://t.co/OAW670OP15

[Biocat @biocat_en]

More than 2,000 top executives visit #BES13 in Barcelona : http://t.co/w5ojRmRnpa

[Clarivate for Life Sciences & Healthcare @ClarivateHealth]

Lykera Biomed's F. Mitjans explains types of potential collaborations for company's compounds, including LK1-S100A4 and LK3-S100P. #BES13

[Lykera Biomed @Lykera]

Come to the Lykera’s company presentation today at 10:30 AM, room 118, Level 1 http://t.co/PWCRO16dXU #cancer #reasearch #BES13

[Biocat @biocat_en]

2nd day promoting the BioRegion of Catalonia at BIO-Europe Spring Barcelona. Biocat booth (number 25) #BES13: http://t.co/guxBj0uKrB

[Lykera Biomed @Lykera]

Press release #lavanguardia #bes13 http://t.co/vVmKwuQb4D

[Lykera Biomed @Lykera]

First in class moab #pancreatic #cancer
with In vivo Poc under hunanization ready for licence, further info Wed, @10.30 #bes13

[FierceBiotech @FierceBiotech]

U.K. Catalyst fund injects $70M into new generation of biotechs http://t.co/JnlnLPRyfN #VC #biotech